With these considerations, creating a denosumab-like monoclonal antibody with a FAPα-cleavable peptide that only activates in FAP-expressing FD lesions could allow sustained therapy by eliminating off-target effects and potentially promote local reactivation of normal bone turnover as lesions normalize their cellular composition and reduce FAP expression. Here, FAP is linked to Fabry disease.